Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat.

The global Pulmonary Arterial Hypertension (PAH) market was valued at 5960 million US$ in 2018 and will reach 9970 million US$ by the end of 2025, growing at a CAGR of 6.7% during 2019-2025.
This report focuses on Pulmonary Arterial Hypertension (PAH) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Arterial Hypertension (PAH) market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Pulmonary Arterial Hypertension (PAH) in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Pulmonary Arterial Hypertension (PAH) manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5

Segment by Application
Hospital
Clinic